Attachment Inhibition Therapeutics: Ethical Considerations Part 2

Simon Raymond, Melbourne University, Australia.

Abstract

To date, immunization has consisted of two principle pathways: (1) replication of infective agent; (2) enhancement of immune function. Given the lack of success of the two current pathways, the current researcher (author) has conceptualised (developed) the new, or third, pathway of site attachment inhibition. The methodology surrounding site attachment inhibition therapeutics has been discussed in previous lectures (Reference Citations 1-9). It involves both medication based treatment of established infections and preventative immunization (new generation; stem cell therapy based). New generation immunization involves stem cell therapy (including mutagenesis and knockout) of particular genetic targets such to achieve immunity (resistance) to infectious agents that is similar to what occurs with hereditary genetic variations/mutations).

The methodology for identifying genetic targets has been discussed in previous lectures. In brief, “Using methodology relating to CRISPR, CRISPR Cas 9 and related technologies would allow comparison between cells in which entry of the pathogen is occurring to those in which entry of the pathogen is not occurring (or, not able to) and through analysis of the genetics of the human cellular biology used by the pathogen to gain cellular attachment (or, transfer and entry), the genes to be targeted in mutagenesis and knockout can be analysed. The pathogen machinery also is to be analysed.” From the above, it is clear that the current research has directed a methodology that encourages ascertainment of the genetic targets by way of first principles as opposed to direct copying. Direct copying may be considered a more ownership type attitude toward the genetics of humans and other species.

Biography:

Simon Raymond is a Consultant specialising in Medical and Scientific Research and an Alumnus of Melbourne University (Rank of Number 1 in Australia and Number 33 in the World). The above-stated Researcher has acted as a Reviewer for the respected Medical Journal of Australia, has received invitations internationally to review from prestigious medical journals including Journal of American Medical Association Network. He has received award in recognition of his research by Royal Australasian College of Surgeons (PSC, 2006) and invited to conferences internationally as an official Delegate and Researcher, including that in USA and China. He has worked as the Principle Researcher in the highest-powered form of medical trial—Randomised Controlled Trial (RCT). The above-stated Researcher is also a Member of the Golden Key International Society for Honoured and outstanding Academics and has been cited as a Notable Global Leader.

EuroScicon Conference on Cancer Stem Cell and Oncology Research: August 24-25, 2020

Abstract Citation: